Facultad de Medicina (FM)
Centro académico
Humanitas University
Rozzano, ItaliaPublications en collaboration avec des chercheurs de Humanitas University (30)
2024
-
An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial
The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
-
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
European Journal of Cancer, Vol. 208
2023
-
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422
-
Combination immunotherapy for hepatocellular carcinoma
Journal of Hepatology, Vol. 79, Núm. 2, pp. 506-515
-
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
Frontiers in Medicine, Vol. 10
-
Exploring the EVolution in PrognOstic CapabiLity of MUltisequence Cardiac MagneTIc ResOnance in PatieNts Affected by Takotsubo Cardiomyopathy Based on Machine Learning Analysis: Design and Rationale of the EVOLUTION Study
Journal of Thoracic Imaging, Vol. 38, Núm. 6, pp. 391-398
-
In Vivo Analysis of Tumor-Associated Macrophages in the Tumor Microenvironment
Methods in Molecular Biology (Humana Press Inc.), pp. 93-108
-
Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial
Journal of Clinical Oncology
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516
-
Protective ileostomy creation after anterior resection of the rectum: Shared decision-making or still subjective?
Colorectal Disease, Vol. 25, Núm. 4, pp. 647-659
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
Biomedicines, Vol. 10, Núm. 7
-
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
ESMO Open, Vol. 7, Núm. 5
-
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750
-
Reply to: “An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously”
Journal of Hepatology
-
The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres
European Journal of Cancer, Vol. 177, pp. 72-79
2021
-
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
Investigational New Drugs, Vol. 39, Núm. 4, pp. 1028-1035
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609